NCT03830762 - Xanamem™ in Healthy Elderly Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

December 7, 2019

Study Completion Date

January 7, 2020

Conditions

SafetyPeripheral NeuropathyCortisolCentral Nervous SystemCognitive FunctionHealthy AgeingSmall Fibre NeuropathyCerebrospinal FluidElectrocardiography

Interventions

DRUG

Xanamem

Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.

DRUG

Matching Placebo

Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.

Trial Locations (1)

6009

Linear Clinical Research, Perth